Amgen said it agreed to buy BioVex, a closely held maker of experimental cancer drugs, for $425 million and as much as $575 million in milestone payments.
BioVex’s lead product, the experimental cancer vaccine Oncovex, is in the final stages of testing usually required for regulatory approval. It treats metastatic melanoma, a skin cancer. The drug also is being studied in head and neck cancer, the companies said.
via nytimes.com
No comments:
Post a Comment